QR kód

Survival Outcomes of Gemcitabine–Cisplatin–S‐1 Versus Gemcitabine–Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery

ABSTRACT Background Gemcitabine plus cisplatin (GC) has been the global standard for advanced biliary tract cancer (BTC). The triplet regimen gemcitabine–cisplatin–S‐1 (GCS) demonstrated superiority in the MITSUBA trial, but its real‐world effectiveness remains unclear. We compared survival outcomes...

Celý popis

Uloženo v:
Hlavní autoři: Hisashi Kosaka, Masahiko Kinoshita, Satoshi Yasuda, Satoru Kakizaki, Rie Sugimoto, Jun Sakata, Kiyonori Yamai, Takeshi Hatanaka, Yusuke Yamamoto, Toshifumi Sato, Toru Ishikawa, Takanori Morikawa, Jun Hanaoka, Haruki Mori, Hidenori Toyoda, Tsuyoshi Sanuki, Misaki Yokoi, Hiroyuki Shibata, Koji Fukuda, Kazuhito Kawata, Koji Amaya, Takashi Ito, Masaaki Hidaka, Atsushi Naganuma, Keishi Sugimachi, Satoshi Toshiyama, Makoto Yamasaki, Masaki Kaibori
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley 2026-07-01
Edice:Annals of Gastroenterological Surgery
Témata:
biliary tract neoplasms
cholangiocarcinoma
cisplatin
gemcitabine
Tegafur Gimeracil Oteracil potassium (S‐1)
On-line přístup:https://doi.org/10.1002/ags3.70202
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky